Report Library
All ReportsChronic Migraine Survey
January 25, 2017
We conducted a 5-question survey of 26 United States and 25 European (based in France, Germany, Italy, Spain and United Kingdom)
neurologists involved in pain management to gauge current prescribing practices in prophylactic treatment of chronic migraine and potential
future use of the calcitonin gene-related peptide (CGRP) receptor targeting monoclonal antibody (mAb) AMG 334 (AMGN) and CGRP
targeting mAbs ALD403 (ALDR) and TEV-48125 (TEVA).
If you are a KOL Insight Subscriber, please access the survey from our KOL Insight portal (Subscribers only).
Biomedtracker will be offering KOL Reports and Physician Pulse Surveys for purchase a la carte, or access to all reports and surveys can be purchased as a subscription to KOL Insight. For more information on KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (858) 200-2357.
For our disclosures, please read the Biomedtracker Research Standards.
If you are a KOL Insight Subscriber, please access the survey from our KOL Insight portal (Subscribers only).
Biomedtracker will be offering KOL Reports and Physician Pulse Surveys for purchase a la carte, or access to all reports and surveys can be purchased as a subscription to KOL Insight. For more information on KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (858) 200-2357.
For our disclosures, please read the Biomedtracker Research Standards.
Indications Covered: | Migraine and Other Headaches |